Plerixafor+G-CSF–mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapyGaryfalia Karponi, Evangelia Yannaki, Νικόλαος Ζώγας et al.|Blood|2015Cited by 49
Genome-Wide Association Study Points to Novel Locus for Gilles de la Tourette SyndromeFotis Tsetsos, Yves Dion, Apostolia Topaloudi et al.|Biological Psychiatry|2023Cited by 31
Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life AnalysisEleni Gavriilaki, Ioanna Sakellari, Panagiotis Dolgyras et al.|Cancers|2023Cited by 19
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell RecipientsEleni Gavriilaki, Ioannis Papassotiriou, Christos Demosthenous et al.|International Journal of Molecular Sciences|2024Cited by 9
Non‐transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicinePanayotis Kaloyannidis, Αναστασία Παπαδοπούλου, Anastasios Kouimtzidis et al.|British Journal of Haematology|2021Cited by 7